HomeMaribavirMaribavir + Valganciclovir

Does Maribavir Interact with Valganciclovir?

Maribavir and Valganciclovir have a major drug interaction according to U.S. FDA drug labeling data. LIVTENCITY may antagonize the antiviral activity of valganciclovir by inhibiting human CMV pUL97 kinase, which is required for activation/phosphorylation of valganciclovir. Coadministration is not recommended. The mechanism involves inhibition of human cmv pul97 kinase. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Maribavir Class
Cytomegalovirus pUL97 Kinase Inhibitor
Valganciclovir Class
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Maribavir and Valganciclovir occurs because inhibition of human cmv pul97 kinase. Clinically, this means livtencity may antagonize the antiviral activity of valganciclovir by inhibiting human cmv pul97 kinase, which is required for activation/phosphorylation of valganciclovir. coadministration is not recommended. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Maribavir and your doctor is considering prescribing Valganciclovir (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Maribavir(Livtencity)+💊 Valganciclovir

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
Cytomegalovirus pUL97 Kinase Inhibitor
Drug B class
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor
Source
NLP:maribavir

What this means in plain English

LIVTENCITY may antagonize the antiviral activity of valganciclovir by inhibiting human CMV pUL97 kinase, which is required for activation/phosphorylation of valganciclovir. Coadministration is not recommended.

What the FDA label says

"Inhibition of human CMV pUL97 kinase"

📖 Source: NLP:maribavir

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Maribavir and Valganciclovir against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.